Compare TTMI & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTMI | NVAX |
|---|---|---|
| Founded | 1978 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8B | 1.6B |
| IPO Year | 2000 | 1996 |
| Metric | TTMI | NVAX |
|---|---|---|
| Price | $90.53 | $10.24 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 9 |
| Target Price | ★ $98.50 | $11.33 |
| AVG Volume (30 Days) | 1.6M | ★ 4.2M |
| Earning Date | 05-06-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 211.11 | ★ 309.76 |
| EPS | 1.68 | ★ 2.58 |
| Revenue | ★ $2,906,345,000.00 | $1,123,479,000.00 |
| Revenue This Year | $19.46 | N/A |
| Revenue Next Year | $17.05 | N/A |
| P/E Ratio | $53.92 | ★ $4.00 |
| Revenue Growth | 18.98 | ★ 64.69 |
| 52 Week Low | $16.55 | $5.01 |
| 52 Week High | $113.46 | $11.85 |
| Indicator | TTMI | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 43.16 | 55.97 |
| Support Level | $87.37 | $7.81 |
| Resistance Level | $110.38 | $10.42 |
| Average True Range (ATR) | 6.54 | 0.71 |
| MACD | -2.09 | 0.01 |
| Stochastic Oscillator | 9.13 | 38.57 |
TTM Technologies Inc manufactures technology products, including mission systems, RF components, RF/microwave assemblies, and advanced interconnect products such as PCBs and substrates. It operates through three segments: A&D, Commercial, and RF&S Components. The A&D segment supports aerospace and defense missions with PCBs, assemblies, microelectronics, and integrated systems. The Commercial segment, generating the majority of revenue, serves automotive, medical, industrial, and data center markets. The RF&S Components segment provides TTM-designed RF components and COTS products. The Company's revenues come from PCBs, engineered systems, and long-term contracts for intelligence, surveillance, and communications solutions.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.